XML 43 R30.htm IDEA: XBRL DOCUMENT
v3.24.3

Revenue- Incyte Corporation (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | 24 Months Ended | 81 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Aug. 31, 2024 USD ($) | Jun. 30, 2024 USD ($) | Jan. 31, 2022 USD ($) | Sep. 30, 2024 USD ($) | Sep. 30, 2023 USD ($) | Sep. 30, 2024 USD ($) | Sep. 30, 2023 USD ($) | Dec. 31, 2019 USD ($) performanceObligation | Dec. 31, 2017 USD ($) | Dec. 31, 2018 USD ($) | Sep. 30, 2024 USD ($) | Dec. 31, 2023 USD ($) | Jul. 31, 2022 USD ($)
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  | $ 110,708 | $ 10,397 | $ 130,609 | $ 48,029 |  |  |  |  |  |
Deferred revenue, current |  |  |  | 23,308 |  | 23,308 |  |  |  |  | $ 23,308 | $ 21,651 |
Deferred revenue, net of current portion |  |  |  | 55,503 |  | 55,503 |  |  |  |  | 55,503 | 59,243 |
Incyte Corporation | Incyte MGA012 Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable upfront payment |  |  |  |  |  |  |  |  | $ 150,000 |  |  |  |
Potential commercial milestone payments under agreement |  |  |  |  |  |  |  | $ 330,000 |  |  |  |  |
Potential development and regulatory milestone payments under agreement |  |  |  |  |  |  |  | 210,000 |  |  |  |  |
Development and regulatory milestones recognized | $ 100,000 |  |  |  |  |  |  |  |  |  | 215,000 |  |
Collaborative agreement transaction price |  |  |  |  |  |  |  | $ 154,000 |  |  |  |  |
Variable consideration recognized |  |  |  |  |  |  |  |  |  | $ 4,000 |  |  |
Number of performance obligations | performanceObligation |  |  |  |  |  |  |  | 2 |  |  |  |  |
Gilead | Gilead First Research Program |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  | $ 3,300 |  | 400 | 100 | 2,400 | 100 |  |  |  |  |  |
Deferred revenue |  |  |  | 16,400 |  | 16,400 |  |  |  |  | 16,400 | 14,900 |
Deferred revenue, current |  |  |  | 16,400 |  | 16,400 |  |  |  |  | 16,400 | 11,800 |
Deferred revenue, net of current portion |  |  |  |  |  |  |  |  |  |  |  | 3,100 |
Minimum | Incyte Corporation | Incyte MGA012 Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Potential proceeds from royalties (percent) |  |  |  |  |  |  |  | 15.00% |  |  |  |  |
Maximum | Incyte Corporation | Incyte MGA012 Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Potential proceeds from royalties (percent) |  |  |  |  |  |  |  | 24.00% |  |  |  |  |
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  | 100 | 15,000 | 300 | 15,000 |  | $ 150,000 |  |  |  |
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Clinical Services |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  | 200 | 100 | 1,700 |  |  |  |  |  |
Revenues From License Agreements | Incyte Corporation | Incyte Commercial Supply Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  | 500 | 100 | 1,400 | 300 |  |  |  |  |  |
RevenuesFromCMOAgreementsMember | Incyte Corporation |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable upfront payment |  |  | $ 10,000 |  |  |  |  |  |  |  |  |  |
Annual Fixed Payments |  |  | $ 14,400 |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  | 3,800 | $ 4,500 | 8,100 | $ 9,600 |  |  |  |  |  |
Deferred revenue |  |  |  | 4,600 |  | 4,600 |  |  |  |  | 4,600 | 7,000 |
Deferred revenue, current |  |  |  | $ 4,600 |  | $ 4,600 |  |  |  |  | $ 4,600 | $ 7,000 |
RevenuesFromCMOAmendmentAgreement | Incyte Corporation |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Annual Fixed Payments |  |  |  |  |  |  |  |  |  |  |  |  | $ 19,500
Additional Payments |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,100
Manufacturing Services | Incyte Corporation |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Extension term |  |  |  |  |  |  |  |  |  |  |  |  | 1 year
Manufacturing Services | Incyte Corporation | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-02-01 |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue, remaining performance obligation, expected timing of satisfaction |  |  | 3 years |  |  |  |  |  |  |  |  |  |

X
- Definition Additional Annual Fixed Payments + References No definition available. + Details
Name: | mgnx_AdditionalAnnualFixedPayments
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | mgnx_CollaborativeAgreementTransactionPrice
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Development And Regulatory Milestone Payments Under Agreement, Recognized + References No definition available. + Details
Name: | mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | mgnx_NonRefundableUpfrontFees
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | mgnx_NumberOfPerformanceObligations
Namespace Prefix: | mgnx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | mgnx_PotentialCommercialMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | mgnx_ProceedsfromRoyaltiesPercent
Namespace Prefix: | mgnx_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount + References No definition available. + Details
Name: | mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue, Performance Obligation, Extension Term + References No definition available. + Details
Name: | mgnx_RevenuePerformanceObligationExtensionTerm
Namespace Prefix: | mgnx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Total Annual Fixed Payments + References No definition available. + Details
Name: | mgnx_TotalAnnualFixedPayments
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiabilityNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1 Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mgnx_GileadMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_GileadFirstResearchProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012ClinicalServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteCommercialSupplyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAgreementsMemberMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mgnx_RevenuesFromCMOAmendmentAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mgnx_ManufacturingServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-02-01
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |